secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001129928-26-000011
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelareorep data at AACR: 62% ORR in pancreatic cancer; TLS formation in breast cancer
--------------------------------------------------------------------------------

- GOBLET cohort 1: 62% objective response rate in first-line mPDAC, more than double historical chemotherapy alone.
- Patients with immune activation signature had median PFS 7.5 months vs 5.6 months for those without.
- AWARE-1 breast cancer study: pelareorep drove tertiary lymphoid structure formation in select patients.
- Pelareorep stimulated RAS-specific T-cell clones in gastrointestinal cancers, presented at a future meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000011/0001129928-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000011/oncy-20260319.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer